연구동향 분석
박사

(The) role of KLF5 and its mechanism for treatment resistance in preoperative chemoradiation therapy for rectal cancer

김정연 2015년

논문상세정보
인용/피인용
' (The) role of KLF5 and its mechanism for treatment resistance in preoperative chemoradiation therapy for rectal cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • klf5
  • preoperative chemoradiation therapy
  • prognostic factor
  • rectal cancer
  • 예측인자
  • 직장암
  • 항암방사선치료
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
117 0

0.0%

' (The) role of KLF5 and its mechanism for treatment resistance in preoperative chemoradiation therapy for rectal cancer' 의 참고문헌

  • Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectaltumor response to preoperative radiotherapy. Cancer. 2005;104:2517?21.
  • Zaho Y, Hamza MS, Leong HS, Lim CB, Pan YF, Cheung E et al.Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1survival kinase in cancer cells. Ongocene. 2008:27(1):1-8
  • Yang Y, Goldstein BG, Nakagawa H, Katz JP. Kruppel-like factor 5 activatesMEK/ERK signaling via EGFR in primary squamous epithelial cells. FASEB J.2007;21:543?550
  • Wheeler JM, Dodds E, Warren BF, Cunningham C, George BD, Jones AC, etal. Preoperative chemoradiotherapy and total mesorectal excision surgery forlocally advanced rectal cancer: correlation with rectal cancer regression grade.Dis Colon Rectum. 2004;47:2025?3129
  • Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES,Balducci M, et al. The relationship of pathologic tumor regression grade (TRG)andoutcomes after preoperative therapy in rectal cancer. Int J Radiat OncolBiol Phys. 2005;62:752?60
  • Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A ,et al. Does downstaging predict improved outcome after preoperativechemoradiation for extraperitoneal locally advanced rectal cancer? A long- termanalysis of 165 patients. Int J Radiat Oncol Biol Phys. 2002;53:664?74.
  • Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase(platelet-derived endothelial-cell growth factor) in cancer biology and treatment.Lancet Oncol. 2005;6:158?66.
  • Taieb J, Tabernero J, Mini E Subtil F, Folprecht G, Van Laethem JL, et al.Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patientswith resected stage III colon cancer (PETACC-8): an open-label, randomisedphase 3 trial. Lancet Oncol. 2014;15(8):862-73
  • Smith FM, Reynolds JV, Kay EW, Crotty P, Murphy JO, Hollywood D, etal. COX-2 overexpression in pretreatment biopsies predicts response of rectalcancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys.2006;64:466?72.
  • Rosty C, Young JP, Walsh MD Clendenning M, Walters RJ, Pearson S.32Colorectal carcinomas with KRAS mutation are associated with distinctivemorphological and molecular features. Mod Pathol. 2013;26(6):825?34.
  • Rodel F, Hoffmann J, Distel L, Janschek E, Ploner M, Hofbauer F, et al.Survivin as a radioresistance factor, and prognostic and therapeutic target forradiotherapy in rectal cancer. Cancer Res. 2005;65:4881?87.
  • Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression ofthe angiogenic factors vascular endothelial cell growth factor, acidic and basicfibroblast growth factor, tumor growth factor beta-1, platelet-derived31endothelial cell growth factor, placenta growth factor, and pleiotrophin inhuman primary breast cancer and its relation to angiogenesis. Cancer Res.1997;57:963?9.
  • Reerink O, Karrenbeld A, Plukker JT, Verschueren RC, Szabo BG, SluiterWJ, et al. Molecular prognostic factors in locally irresectable rectal cancertreated preoperatively by chemo-radiotherapy. Anticancer Res.2004;24(2C):1217?21.
  • Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA. Molecularprognostic factors in rectal cancer treated by radiation and surgery. Dis ColonRectum. 2000;43: 451?9.
  • Normanno N, Tejpar S, Morgillo F De Luca A, Van Cutsem E, Ciardiello F.Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.Nat Rev Clin Oncol. 2009;6(9):519?27.
  • Negri FV, Campanini N, Camisa R, Pucci F, Bui S, Ceccon G, et al.Biological predictive factors in rectal cancer treated with preoperativeradiotherapy or radiochemotherapy. Br J Cancer. 2008;98:143?7.
  • Nandan MO, Yoon HS, Zhao W Yang VW. Kruppel-like factor 5mediates the transforming activity of oncogenic H-Ras. Oncogene 2004;23:3404?13.
  • Nandan MO, McConnell BB, Ghaleb AM, Bialkowska AB, Sheng H, ShaoJ, et el. Kruppel-like factor 5 mediates cellular transformation during oncogenicKRAS-induced intestinal tumorigenesis. Gastroenterology 2008;134:120?130
  • Nandan MO, Chanchevalap S, Dalton WB, Yang VW. Kruppel-likefactor 5promotes mitosis by activating the cyclin B1/Cdc2 complex during oncogenicRas-mediated transformation. FEBS Lett 2005;579: 4757?62.30
  • M Lee, J Moon, SW park Baik SH, Lee KY, Koom WS, et al. KLF5enhances SREBP-1 action in androgen-dependent induction of fatty acidsynthase in prostate cancer cells. J Biol Chem 2009;417:313-22
  • Liu Y, Wen JK, Dong LH, Zheng B, Han M. Kruppel-like factor (KLF) 5mediates cyclin D1 expression and cell proliferation via interaction with c-Junin Ang II-induced VSMCs. Acta Pharmacol Sin. 2010;31:10?18
  • Lin JT, Chang TH, Chang CS, Wang WH, Su BW, Lee KD, et al.Prognostic value of pretreatment CD44 mRNA in peripheral blood of patientswith locally advanced head and neck cancer. Oral Oncol. 2010;46:29?33.
  • Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, et al.TP53 genotype but not p53 immunohistochemical result predicts response topreoperative short-term radiotherapy in rectal cancer. Ann Surg.2002;235:493?8.
  • Kaminsky-Forrett MC, Conroy T, Luporsi E, Peiffert D, Lapeyre M, BoisselP, et al. Prognostic implications of downstaging following preoperativeradiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol BiolPhys.281998;42:935?41
  • Improved survival with preoperative radiotherapy in resectable rectal cancer.Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980?87.
  • Hur H, Kim NK, Min BS, Baik SH, Lee KY, Koom WS, et al. Can abiomarker-based scoring system predict pathologic complete response afterpreoperative chemoradiotherapy for rectal cancer? Dis Colon Rectum. 2014;57:592?01.
  • Huh JW, Park YA, Jung EJ, Lee KY, Sohn SK. Accuracy of endorectalultrasonography and computed tomography for restaging rectal cancer afterpreoperative chemoradiation. J Am Coll Surg. 2008;207:7?12.
  • Huh JW, Min JJ, Lee JH, Kim HR, Kim YJ, et al. The predictive role ofsequential FDG-PET/CT in response of locally advanced rectal cancer toneoadjuvant chemoradiation. Am J Clin Oncol. 2012;35:340?4.
  • Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, et al.Identification of a biomarker profile associated with resistance to neoadjuvantchemoradiation therapy in rectal cancer. Ann Surg. 2011;254:486-92.
  • Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, et al.Response to preoperative chemoradiation increases the use ofsphincter-preserving surgery in patients with locally advanced low rectalcarcinoma. Cancer. 2003;97:517?24.
  • Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, et al. Bax, apredictive marker for therapeutic response to preoperative chemoradiotherapy inpatients with rectal carcinoma. Hum Pathol. 2005;36:364?71.
  • Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, etal. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperativeradiotherapy in rectal cancer. N Engl J Med. 2006;355:1114?23.
  • Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, et al.Prognostic and predictive value of baseline and post treatment molecularmarker expression in locally advanced rectal cancer treated with neoadjuvantchemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1455?61.
  • Bateman NW, Tan D, Pestell RG et al. Intestinal tumor progression isassociated with altered function of KLF5. J Biol Chem 2004; 279: 12093?101.